The CSL Limited (ASX: CSL) share price rocketed 15.6% higher in August, aided by a full-year profit result that beat its upgraded guidance from May.
Full-year profit for the 12 months ending 30th June 2018 of $1729 million was delivered, up 29% on the same period a year earlier.
The vaccines and blood products supplier said sales revenue for the year to June 30 rose 14.7% to $US7.59 billion.
On a per-share basis, the company said it had a profit of 382 cents. This compares with a profit of 294 cents per share in the corresponding period last year. The company declared a full year dividend for the period of 172 cents per share, an increase of 26%.
CSL shares have had a wonderful run in 2018, rising from $140.55 to as high as $232.69 in late August.
In providing guidance, CSL said it expects 2018/19 net profit in constant currency terms to be in the range of $US1.88 billion to $US1.95 billion, an increase of 10-14% from 2017/18.
Since early September, CSL shares have drifted lower in a falling share market, the ASX 200 constituent now trading at $210.62.
CSL trades on a price to earnings (P/E) ratio of around 40 times earnings. CSL shares trade on a fully franked dividend yield of 1.2%.